Combined injectable contraceptive
| Combined Injectable Contraceptive |
|---|
| Background |
|---|
| Birth control type |
Hormonal |
|---|
| First use |
about 1980 |
|---|
| Failure rates (first year) |
|---|
| Perfect use |
0-0.2%[1] |
|---|
| Typical use |
? |
|---|
| Usage |
|---|
| Duration effect |
1 month |
|---|
| User reminders |
? |
|---|
| Advantages and disadvantages |
|---|
| STD protection |
No |
|---|
| Benefits |
Especially good if poor pill compliance. |
|---|
Combined injectable contraceptive (CIC) monthly injection of a progestin and a synthetic estrogen taken to suppress fertility. Brand names include Cyclofem, Novafem, Mesigyna, Lunelle and Cyclo-Provera.
DMPA is a different injectable contraceptive, containing just a progestin, given every three months.
History
- October 5, 2000, Pharmacia received FDA approval for Lunelle Monthly Contraceptive Injection.[1]
- April 2003, Pharmacia acquired by Pfizer (makers of Depo-Provera (DMPA)).
- October 2003, Lunelle was discontinued in the U.S.
Use and packaging
Administered by intramuscular injection into the deltoid, gluteus maximus, or anterior thigh.[1] Ideally administered every 28 to 30 days, though demonstrated to be effective up to 33 days.[1]
Side-effects
The most prominent side effects are menstrual irregularities during the first 3 to 6 months of use.[1]
Formulations
See also
Footnotes
PATH (formerly Program for Appropriate Technology in Health) |
|---|
| | Key people | |
|---|
| | Projects | |
|---|
| | Products | |
|---|
|